Clinical trial NCT05201521: Chinese FMDs Registry
Official title: The Chinese Functional Movement Disorders Registry Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Functional Movement Disorders
Lead sponsor: Ruijin Hospital
Sponsor class: OTHER
First posted: 2022-01-21
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: At least 100 patents coming from hospitals or communities in mainland China

Brief summary: The purpose of the Chinese Functional Movement Disorders Registry (FMDs-China) is to develop a database of patients with Functional Movement Disorders (FMDs) in China.

Detailed description: Functional movement disorders (FMDs), also known as psychogenic movement disorders (PMDs), formerly known as "hysteria or hysteria", is a representative functional nervous system disease. It has been reported in Europe and America that FMDs patients account for 3% - 6% of all patients in the outpatient department of motor disorders, but there is no relevant data report in China so far. From the current research, the incidence rate has gradually increased significantly. However, the research about the pathogenesis and diagnosis of such diseases is rare. These studies have the problem of small sample size and still lack large randomized controlled studies to demonstrate the long-term efficacy of different treatments. And in China, there are nearly no reliable research and the lack of basic understanding makes it a "gray area" for the diagnosis and treatment of FMDs.

The purpose of this observational study is to prospectively register the information of patients with FMDs nationwide, establishing a Chinese multicenter FMDs China cohort; understanding the demographic characteristics, clinical characteristics and symptom characteristics, neuropsychological test, electrophysiological and imaging characteristics, drug use, etc. what's more, it lays a foundation for the research on the etiology and treatment in the second stage of this study.

Eligibility criteria: Inclusion Criteria:

* Male or female;
* Age 18-80;
* Patients clinically diagnosed with functional movement disorders according to the Fahn-Williams criteria;
* Patients who are willing to provide information such as disease history and cooperate with physical examination and examination;

Exclusion Criteria:

* Patients with definite organic dyskinesia;
* There are other causes of dyskinesia such as fatigue, pain, hyperthyroidism, chronic alcoholism, and drug use;
* Those who suffer from serious physical diseases and are unable to cooperate;
* Those who do not cooperate or refuse to sign informed consent.

Primary outcomes:
measure: The symptom characteristics
timeFrame: baseline
measure: The symptom characteristics
timeFrame: 0.5 years
measure: The symptom characteristics
timeFrame: 1.5 years
measure: The symptom characteristics
timeFrame: 2 years
measure: The movement disorder attack video
timeFrame: baseline
measure: The movement disorder attack video
timeFrame: 0.5 years
measure: The movement disorder attack video
timeFrame: 1.5 years
measure: The movement disorder attack video
timeFrame: 2 years
measure: The Simplified Functional Movement Disorders Rating Scale
timeFrame: baseline
measure: The Simplified Functional Movement Disorders Rating Scale
timeFrame: 0.5 years
measure: The Simplified Functional Movement Disorders Rating Scale
timeFrame: 1 years
measure: The Simplified Functional Movement Disorders Rating Scale
timeFrame: 1.5 years
measure: The Simplified Functional Movement Disorders Rating Scale
timeFrame: 2 years
Secondary outcomes:
measure: Hamilton Depression Scale
timeFrame: baseline
measure: Hamilton Depression Scale
timeFrame: 0.5 years
measure: Hamilton Depression Scale
timeFrame: 1 years
measure: Hamilton Depression Scale
timeFrame: 1.5 years
measure: Hamilton Depression Scale
timeFrame: 2 years
measure: Beck Anxiety Inventory
timeFrame: baseline
measure: Beck Anxiety Inventory
timeFrame: 0.5 years
measure: Beck Anxiety Inventory
timeFrame: 1 years
measure: Beck Anxiety Inventory
timeFrame: 1.5 years
measure: Beck Anxiety Inventory
timeFrame: 2 years
measure: symptom check list-90
timeFrame: baseline
measure: symptom check list-90
timeFrame: 0.5 years
measure: symptom check list-90
timeFrame: 1 years
measure: symptom check list-90
timeFrame: 1.5 years
measure: symptom check list-90
timeFrame: 2 years
measure: clinical global impression severity scale
timeFrame: baseline
measure: clinical global impression severity scale
timeFrame: 0.5 years
measure: clinical global impression severity scale
timeFrame: 1 years
measure: clinical global impression severity scale
timeFrame: 1.5 years
measure: clinical global impression severity scale
timeFrame: 2 years
measure: Clinical global improvement scale
timeFrame: baseline
measure: Clinical global improvement scale
timeFrame: 0.5 years
measure: Clinical global improvement scale
timeFrame: 1 year
measure: Clinical global improvement scale
timeFrame: 1.5 years
measure: Clinical global improvement scale
timeFrame: 2 years
Other outcomes:
measure: The symptom characteristics
timeFrame: 1 years
Locations:
city: Shanghai
country: China
facility: Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
state: Shanghai
Study officials:
affiliation: Ruijin Hospital
name: Gang Wang, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References: